CSTL

CASTLE BIOSCIENCES INC

Healthcare | Small Cap

-$0.29

EPS Forecast

$96.58

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Castle Biosciences (CSTL) Upgrades 2026 Revenue Forecast as Q3 Revenue Rides Test-Report Momentum

In a quarter where a handful of diagnostic tests moved from niche to notable, Castle Biosciences’ third quarter highlights push the revenue forecast higher while keeping EPS details out of sight. The company’s press release signals continued demand for its DecisionDx and TissueCypher panels, with implications for peers in dermatologic and molecular diagnostics.

Financial snapshot: top-line momentum, no EPS yet on the board

Castle Biosciences, Inc. (Nasdaq: CSTL) reported revenue of $102.9 million for the third quarter ended September 30, 2026, up 24% from $83.0 million in the prior-year period. The company also highlighted strong year-to-date activity and maintained a focus on cash generation, reporting net cash provided by operating activities of $19.7 million for the quarter.

As is typical for a growth-forward diagnostics company, the release emphasizes test-volume and mix shifts rather than an immediately visible EPS figure. Consequently, there is no stated earnings surprise or EPS consensus in the press materials, leaving investors to interpret the quarter through revenue quality and conservative profitability signals rather than a reported per-share result.

Product momentum: TissueCypher and DecisionDx lead the way

The company framed quarterly strength around its core revenue drivers and an expanding portfolio:

  • TissueCypher test volumes rose 47% YoY, underscoring demand for innovative assays in Barrett’s Esophagus and related indications.
  • DecisionDx-Melanoma test reports delivered in Q3 totaled 10,177, versus 10,459 in Q3 2025, illustrating continued—though modest—growth in this flagship melanoma panel.
  • TissueCypher Barrett’s Esophagus reports came in at 15,574, up from 10,609 in the prior-year period, signaling outsized growth in a key clinical segment.
  • Other assays, notably DecisionDx-SCC and MyPath Melanoma, contributed to the mix, though the quarter showed differential quarterly performance across tests.

Overall, the mix shift points to a portfolio strategy that leverages high-value tests while expanding volume in established panels—an approach that tends to translate into steadier quarterly revenue reads even as individual test outcomes swing.

Guidance and what it portends for the stock and peers

Castle raised its full-year 2026 revenue forecast to a range of $385-395 million from the prior $365-375 million corridor. That upgrade, coming alongside the Q3 revenue beat, situates the company on a higher trajectory for the balance of 2026 and into 2027—assuming test volumes hold and payer coverage remains supportive.

The raised forecast is a meaningful signal for investors: management expects continued demand for its test offerings and a more favorable mix that supports top-line expansion without a commensurate immediate downgrade of margins. In the context of peers in dermatologic diagnostics and personalized medicine, the message is that differentiated panels with proven clinical value can sustain growth even as larger cap diagnostic players remain sensitive to reimbursement and utilization trends.

Management perspective

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio,” said Derek Maetzold, Castle Biosciences’ president and chief executive officer. “TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume in the quarter.”

The CEO’s remarks emphasize operational discipline and portfolio diversification as the dual engines behind repeatable growth. The narrative—focusing on cash flow generation alongside test-volume expansion—also hints at potential leverage as the company navigates a slower ramp in some newer panels and a faster ramp in established ones.

What this could mean for Castle and sector peers

From a market structure view, the quarter reinforces a few durable truths about diagnostic services in oncology-dedicated platforms:

  • Product mix matters: The outsized contribution from TissueCypher suggests that high-value, line-extensions can compound revenue growth even when volume in some legacy tests trends modestly.
  • Reinforced guidance can attract a different class of investor: those who look for visibility in full-year revenue growth rather than quarterly EPS flimsies.
  • Volume signals may presage payer and adoption dynamics: rising test reports imply broader clinician acceptance and potential network effects as more physicians use Castle’s panels.

Peers in dermatologic oncology diagnostics could interpret Castle’s trajectory as a compendium of two signals: (i) success in expanding test volumes for existing panels, and (ii) a willingness to raise revenue targets when product mix is favorable. The combination may press competitors to focus not only on raw test counts but on the clinical impact and downstream adoption that drive payer acceptance and rate setting.

What to watch next

Investors will be watching for:

  • Further quarterly data on test volumes, especially in DecisionDx and TissueCypher lines, to gauge whether momentum persists into the holiday season and early 2027.
  • Any forthcoming disclosures on EPS or per-share results to anchor the current revenue narrative with profitability metrics, potentially shaping earnings surprise expectations.
  • Reimbursement developments and payer mix shifts, which could alter the sustainability of the elevated revenue forecast.

Bottom line

Castle Biosciences’ Q3 2026 results deliver a clean narrative: revenue acceleration backed by test-volume expansion in flagship panels, paired with a higher full-year revenue forecast. The absence of a disclosed EPS figure leaves the EPS consensus debate to a future earnings release, but the cash-flow backdrop and robust top-line trajectory provide a practical lens through which to evaluate CSTL against its dermatologic-diagnostics peers. In short: the company’s numbers aren’t a magic wand, but the wand is waving in the right direction, and the wand-waving business model looks increasingly durable for the year ahead.

For readers tracking CSTL, the next quarterly update should clarify whether the earnings per share line finally joins the party and whether the revenue forecast proves stickier than a test result with surprising color charts. In the meantime, the market gets a clearer sense of where Castle’s core products live in a world increasingly biased toward precise, actionable diagnostics.